Elacridar Reverses P-gp-Mediated Drug Resistance in Ovarian Cancer Cells in 2D and 3D Culture Models
International Journal of Molecular Sciences · 16.12.2025 · 26 (24) · 12105
DOI: 10.3390/ijms262412105 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 16.12.2025. Verfasst von Piotr Stasiak und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biological Sciences, University of Zielona Góra, 65-417 Zielona Góra, Poland. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Ovarian Neoplasms, Acridines, Tetrahydroisoquinolines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Centre.
Abstract (Originalsprache)
Multidrug resistance (MDR) remains a major obstacle in the treatment of ovarian cancer. MDR is often mediated by the overexpression of ATP-binding cassette (ABC) transporters, such as P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP). In this study, we evaluated the ability of elacridar, a dual P-gp and BCRP inhibitor, to overcome MDR in W1, an ovarian cancer cell line sensitive to Paclitaxel (PAC) and its PAC-resistant variants. Cells were cultured under both two-dimensional (2D) and three-dimensional (3D) conditions to account for differences in tumor-like microenvironments. The MDR1 gene and P-gp protein expression were determined for the analyzed model; P-gp activity was measured by flow-cytometry and fluorescent observation, with and without elacridar. The MTT tests were carried out to evaluate how elacridar, combined with chemotherapeutics, affects cell viability. Our results demonstrate that elacridar effectively inhibited transporter activity and increased cellular sensitivity to PAC and DOX. The inhibitory effect was observed in both 2D and 3D cultures, although the re-sensitization effect in 3D conditions was less pronounced, reflecting the complexity of tumor-specific resistance mechanisms. These findings highlight elacridar as a promising compound for reversing MDR in ovarian cancer and emphasize the importance of 3D models in preclinical drug evaluation. Further studies in advanced in vitro and in vivo models are required to assess the potential of elacridar better.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biological Sciences, University of Zielona Góra, 65-417 Zielona Góra, Poland.
- The Doctoral School of Exact and Technical Sciences, University of Zielona Góra, 65-417 Zielona Góra, Poland.
- Institute of Health Sciences, Collegium Medicum, University of Zielona Góra, 65-417 Zielona Góra, Poland.
- Department of Histology and Embryology, Doctoral School, Poznan University of Medical Sciences, 61-701 Poznań, Poland.
- Department of Histology and Embryology, Poznan University of Medical Sciences, 61-701 Poznań, Poland.
ORCID-Profile: Piotr Stasiak, Justyna Sopel, Agnieszka Anna Rawłuszko-Wieczorek, Karolina Sterzyńska, Jan Korbecki, Radosław Januchowski
Förderung
- National Science Centre
Zitieren
APA
Stasiak, P., Sopel, J., Lipowicz, J. M., Rawłuszko-Wieczorek, A. A., Sterzyńska, K., Korbecki, J., & Januchowski, R. (2025). Elacridar Reverses P-gp-Mediated Drug Resistance in Ovarian Cancer Cells in 2D and 3D Culture Models. International Journal of Molecular Sciences, 26(24), 12105. https://doi.org/10.3390/ijms262412105
Vancouver
Stasiak P, Sopel J, Lipowicz JM, Rawłuszko-Wieczorek AA, Sterzyńska K, Korbecki J, et al. Elacridar Reverses P-gp-Mediated Drug Resistance in Ovarian Cancer Cells in 2D and 3D Culture Models. International Journal of Molecular Sciences. 2025;26(24):12105. doi:10.3390/ijms262412105
BibTeX
@article{Stasiak2025,
author = {Stasiak, Piotr and Sopel, Justyna and Lipowicz, Julia Maria and Rawłuszko-Wieczorek, Agnieszka Anna and Sterzyńska, Karolina and Korbecki, Jan and Januchowski, Radosław},
title = {Elacridar Reverses P-gp-Mediated Drug Resistance in Ovarian Cancer Cells in 2D and 3D Culture Models},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {24},
pages = {12105},
doi = {10.3390/ijms262412105}
}
EUVIMED